Yarrow Bioscience (YARW)
Market Price (11/5/2026): $15.3 | Market Cap: $142.4 MilSector: Health Care | Industry: Biotechnology
Yarrow Bioscience (YARW)
Market Price (11/5/2026): $15.3Market Cap: $142.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -128% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -14 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8735% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 548% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 769% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -128% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -14 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8735% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 548% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 769% |
Qualitative Assessment
AI Analysis | Feedback
Yarrow Bioscience (YARW) stock has lost about 55% since 7/31/2026 because of the following key factors:
1. Significant Fiscal Q2 2026 Earnings Miss: Yarrow Bioscience (YARW) reported its fiscal Q2 2026 financial results on August 13, 2026, which substantially missed analyst expectations. The company announced an Earnings Per Share (EPS) of -$3.51, far below the consensus estimate of -$0.18, and reported quarterly revenue of $0.10 million, falling short of analyst estimates of $0.20 million. This considerable miss in both top and bottom-line figures likely triggered a negative market reaction.
2. Share Dilution from Public Offering: In September 2026, Yarrow Bioscience undertook an underwritten public offering, pricing 6,634,615 common shares at $26.00 per share, resulting in approximately $172.5 million in gross proceeds. While intended to fund research and development for its pipeline, this offering significantly increased the number of outstanding shares, leading to dilution for existing shareholders and typically exerting downward pressure on the stock price.
Show more
Yarrow Bioscience (YARW) stock has lost about 55% since 7/31/2026 because of the following key factors:
1. Significant Fiscal Q2 2026 Earnings Miss: Yarrow Bioscience (YARW) reported its fiscal Q2 2026 financial results on August 13, 2026, which substantially missed analyst expectations. The company announced an Earnings Per Share (EPS) of -$3.51, far below the consensus estimate of -$0.18, and reported quarterly revenue of $0.10 million, falling short of analyst estimates of $0.20 million. This considerable miss in both top and bottom-line figures likely triggered a negative market reaction.
2. Share Dilution from Public Offering: In September 2026, Yarrow Bioscience undertook an underwritten public offering, pricing 6,634,615 common shares at $26.00 per share, resulting in approximately $172.5 million in gross proceeds. While intended to fund research and development for its pipeline, this offering significantly increased the number of outstanding shares, leading to dilution for existing shareholders and typically exerting downward pressure on the stock price.
3. Continued Cash Burn and Clinical Stage Risks: As a clinical-stage biotechnology company, Yarrow Bioscience is characterized by significant research and development expenses and a lack of substantial revenue generation, leading to continued cash burn. The reported net loss of $6.5 million for fiscal Q2 2026 highlights this operational characteristic. Despite a successful merger and financing efforts that are expected to fund operations into 2028, the market's perception of risk remains elevated given that the lead product candidate, YB-101, is still in Phase 2a/2b trials, with topline Phase 2a results anticipated in fiscal Q4 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
The -57.4% change in YARW stock from 7/31/2026 to 11/4/2026 was primarily driven by a 0.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312026 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 35.02 | 14.91 | -57.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | � | 0.0% |
| Net Income Margin (%) | � | � | 0.0% |
| P/E Multiple | � | � | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | 0.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| YARW | -57.4% | |
| Market (SPY) | 2.6% | 7.1% |
| Sector (XLV) | 16.7% | -2.4% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| YARW | ||
| Market (SPY) | 7.0% | 7.8% |
| Sector (XLV) | 30.5% | -9.0% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 11/4/2026| Return | Correlation | |
|---|---|---|
| YARW | ||
| Market (SPY) | 13.4% | 7.8% |
| Sector (XLV) | 33.2% | -9.0% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 11/4/2026| Return | Correlation | |
|---|---|---|
| YARW | ||
| Market (SPY) | 89.7% | 7.8% |
| Sector (XLV) | 59.5% | -9.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| YARW Return | - | - | - | - | - | -47% | -47% |
| Peers Return | -15% | 31% | 25% | -17% | 17% | 22% | 64% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| YARW Win Rate | - | - | - | - | - | 20% | |
| Peers Win Rate | 47% | 50% | 48% | 43% | 53% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| YARW Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -47% | -42% | -37% | -39% | -40% | -36% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRDN, IMVT, DNLI, AMGN, REGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/4/2026 (YTD)
How Low Can It Go
YARW has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
YARW has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Yarrow Bioscience (YARW)
Yarrow Bioscience (YARW) is a pharmaceutical company focused on developing a range of therapeutics specifically for immuno-inflammatory conditions. The company's core mission revolves around addressing various diseases, with a particular emphasis on dermatological and other inflammatory disorders through its innovative drug pipeline.
The company's development pipeline includes several key product candidates. FCD105, a topical combination foam, is in late-stage Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris. Additionally, FMX114, a combination of tofacitinib, is in Phase IIa preclinical trials, targeting mild-to-moderate atopic dermatitis.
Beyond these specific applications, Yarrow Bioscience is also advancing VYN201, a bromodomain and extra-terminal (BET) inhibitor, which is being explored for a broad spectrum of immuno-inflammatory diseases, including various skin conditions. Furthermore, the company is developing VYN202, a distinct set of BET inhibitor compounds selectively targeting bromodomain 2. The primary customers for these therapeutics are patients suffering from chronic inflammatory and immune-related diseases, particularly those affecting the skin.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
David Domzalski, President and Chief Executive Officer
Mr. Domzalski has served as President and Chief Executive Officer of VYNE Therapeutics Inc. and a member of its board since March 2020. He previously served as Chief Executive Officer and a board member of Foamix Pharmaceuticals Ltd. starting in July 2017, and as President of Foamix since April 2014. VYNE Therapeutics Inc. was formed through the merger of Foamix Pharmaceuticals Ltd. and Menlo Therapeutics, with Mr. Domzalski, formerly CEO of Foamix, taking the leadership role. His 25 years of industry experience include roles as Vice President of Sales and Marketing at LEO Pharma Inc. (2009-2013), Senior Vice President and General Manager at Azur Pharma (2008-2009), and Vice President of Sales and Marketing at Warner Chilcott (2003-2008).
Tyler Zeronda, Chief Financial Officer, Principal Accounting Officer and Treasurer
Mr. Zeronda was appointed Chief Financial Officer and Treasurer of VYNE Therapeutics Inc. effective March 14, 2022. He had previously served as the company's Interim Chief Financial Officer and Treasurer since June 2021, and before that, as Vice President of Finance. His prior experience includes serving as Finance Director at Aerie Pharmaceuticals, Inc. from 2013 to 2019 and Vice President of Finance at VYNE Pharmaceuticals Ltd. from 2019 to 2020.
Dr. Iain A. Stuart, PhD, Chief Scientific Officer
Dr. Stuart serves as the Chief Scientific Officer of VYNE Therapeutics Inc. He previously held positions as Chief Scientific Officer at Menlo Therapeutics, Inc., Senior Vice President of Research & Development at VYNE Pharmaceuticals Ltd., and Vice President of Medical Strategy & Scientific Affairs at Leo Pharma, Inc.
Mutya Harsch, General Counsel, Chief Legal Officer and Secretary
Ms. Harsch holds the titles of General Counsel, Chief Legal Officer, and Secretary for VYNE Therapeutics Inc.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Share Issuance
- VYNE Therapeutics Inc. conducted a 1-for-50 reverse stock split on July 24, 2026, decreasing its outstanding common stock from approximately 33.4 million shares to about 0.7 million shares.
- Prior to the merger, VYNE Therapeutics' stockholders approved an increase in authorized common shares from 150 million to 300 million.
- Following the merger, the combined entity, Yarrow Bioscience, Inc., has approximately 2.8 million common shares outstanding, or about 28.6 million on a fully diluted basis, including pre-funded warrants.
Inbound Investments
- The reverse merger between Yarrow Bioscience and VYNE Therapeutics Inc. was accompanied by private financings that raised approximately $200 million.
- This $200 million financing is projected to fund the combined company's operations into 2028.
- RTW Biotech Opportunities Ltd invested $5.9 million in Yarrow's Series A funding and an additional $2.4 million in the concurrent PIPE financing.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 29.64 |
| Mkt Cap | 6.2 |
| Rev LTM | 24 |
| Op Inc LTM | -242 |
| FCF LTM | -353 |
| FCF 3Y Avg | -292 |
| CFO LTM | -342 |
| CFO 3Y Avg | -288 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.2% |
| Rev Chg 3Y Avg | 13.3% |
| Rev Chg Q | 8.5% |
| QoQ Delta Rev Chg LTM | 5.4% |
| Op Inc Chg LTM | 2.9% |
| Op Inc Chg 3Y Avg | -26.9% |
| Op Mgn LTM | -1,781.4% |
| Op Mgn 3Y Avg | 25.2% |
| QoQ Delta Op Mgn LTM | 3.0% |
| CFO/Rev LTM | -634.7% |
| CFO/Rev 3Y Avg | 29.9% |
| FCF/Rev LTM | -661.0% |
| FCF/Rev 3Y Avg | 24.2% |
Price Behavior
| Market Price | $14.91 | |
| First Trading Date | 01/25/2018 | |
| Distance from 52W High | -65.3% | |
| 50 Days | 200 Days | |
| DMA Price | $24.30 | |
| DMA Trend | ||
| Distance from DMA | -38.6% | |
| 3M | 1YR | |
| Volatility | 84.1% | 92.0% |
| Downside Capture | 370.70 | |
| Upside Capture | -120.85 | |
| Correlation (S&P 500) | 13.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.26 | 1.11 | 1.45 | 1.21 | 0.15 | 1.33 |
| Up Beta | -16.30 | -0.88 | 2.49 | 0.00 | -4.71 | 0.22 |
| Down Beta | 1.06 | 0.61 | 1.98 | 2.55 | -1.29 | 0.38 |
| Up Capture | -38% | -30% | -37% | 13% | 5% | 0% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 11 | 16 | 23 | 26 | 26 | 26 |
| Down Capture | 144% | 308% | 252% | 112% | 65% | 38% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 11 | 27 | 41 | 41 | 41 | 41 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with YARW | |
|---|---|---|---|---|
| YARW | -47.0% | 92.0% | -2.06 | - |
| Sector ETF (XLV) | 33.1% | 16.7% | 1.53 | -9.0% |
| Equity (SPY) | 13.2% | 12.9% | 0.68 | 7.8% |
| Gold (GLD) | 1.0% | 28.8% | 0.03 | 1.3% |
| Commodities (DBC) | 35.9% | 21.2% | 1.34 | 7.2% |
| Real Estate (VNQ) | 14.3% | 14.1% | 0.70 | -19.7% |
| Bitcoin (BTCUSD) | -28.2% | 43.4% | -0.65 | -12.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with YARW | |
|---|---|---|---|---|
| YARW | -11.9% | 92.0% | -2.06 | - |
| Sector ETF (XLV) | 9.3% | 15.3% | 0.40 | -9.0% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 7.8% |
| Gold (GLD) | 17.3% | 19.1% | 0.73 | 1.3% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | 7.2% |
| Real Estate (VNQ) | 1.8% | 18.9% | -0.01 | -19.7% |
| Bitcoin (BTCUSD) | 5.5% | 51.5% | 0.29 | -12.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with YARW | |
|---|---|---|---|---|
| YARW | -6.1% | 92.0% | -2.06 | - |
| Sector ETF (XLV) | 12.5% | 16.8% | 0.61 | -9.0% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 7.8% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | 1.3% |
| Commodities (DBC) | 7.4% | 18.1% | 0.33 | 7.2% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | -19.7% |
| Bitcoin (BTCUSD) | 61.0% | 66.2% | 1.01 | -12.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 9/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/28/2026 | 8.6% | 35.3% | 41.3% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 0 | 0 | 0 |
| Median Positive | 8.6% | 35.3% | 41.3% |
| Median Negative | |||
| Max Positive | 8.6% | 35.3% | 41.3% |
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/28/2026 | 8.6% | 35.3% | 41.3% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 0 | 0 | 0 |
| Median Positive | 8.6% | 35.3% | 41.3% |
| Median Negative | |||
| Max Positive | 8.6% | 35.3% | 41.3% |
| Max Negative | |||
Recent Forward Guidance
Updated 11/2/2026Latest: Q3 2026 Earnings Reported 7/28/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2028 Cash Runway | Reported | |||||||
| 2028 Phase 2b Commencement | Reported | |||||||
| 2027 Phase 2a Data Readout | Reported | |||||||
Prior: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | Reported | Affirmed | ||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.